Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline Insights, 2014


#222064

N/A

DelveInsight

$ 1250

In Stock

 

The Report will be Dispatched in 3 Working Days. 

 

DelveInsights, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). This report provides information on the therapeutic development based on the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

 

Data Sources

 

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

 

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

 

Scope 

 

  • The report provides a snapshot of the global therapeutic landscape of  Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the  Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for  Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects 
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages 
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

 

Reasons to buy 

 

  • Complete Pipeline intelligence and complete understanding over therapeutics development for  Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
  • Devise corrective measures for pipeline projects by understanding  Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Indication therapeutics  
  • Developing strategic initiatives to support your drug development activities.
  • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
  • Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies  
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
  • Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table of Content

 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Pipeline Therapeutics

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics under Development by Companies 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Late Stage Products (Filed and Phase III)

Comparative Analysis 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Mid Clinical Stage Products (Phase II)

Comparative Analysis 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Early Clinical Stage Products (Phase I and IND Filed)

Comparative Analysis 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Discovery and Pre-Clinical Stage Products 

Comparative Analysis 

Drug Candidate Profiles

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Assessment

Assessment by Monotherapy Products 

Assessment by Combination Products 

Assessment by Route of Administration 

Assessment by Molecule Type 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Discontinued Products 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Dormant Products

Companies Involved in Therapeutics Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) 

 

Appendix 

Methodology 

Contact Us 

Disclaimer

 

Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), 2014

Number of Products under Development by Companies 

Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014

Comparative Analysis Mid Clinical Stage Products (Phase II), 2014

Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014

Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014

Drug Candidates Profiles

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Assessment by Monotherapy Products 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Assessment by Combination Products 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Assessment by Route of Administration 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Assessment by Stage and Route of Administration 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Assessment by Molecule Type 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Assessment by Stage and Molecule Type 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Discontinued Products 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Dormant Products

Products under Development by Companies, 2014

 

Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), 2014

Late Clinical Stage Products (Filed and Phase III), 2014

Mid Clinical Stage Products (Phase II), 2014

Early Clinical Stage Products (Phase I and IND Filed), 2014

Discovery and Pre-Clinical Stage Products, 2014

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Assessment by Monotherapy Products 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Assessment by Combination Products 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Assessment by Route of Administration 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Assessment by Stage and Route of Administration 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Assessment by Molecule Type 

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Assessment by Stage and Molecule Type